OS Therapies (NYSE:OSTX) Stock Rating Upgraded by Brookline Capital Management

OS Therapies (NYSE:OSTX) was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued to investors on Thursday, Zacks.com reports.

OS Therapies Price Performance

NYSE OSTX opened at $4.15 on Thursday. OS Therapies has a twelve month low of $2.51 and a twelve month high of $4.90.

About OS Therapies

OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.